Fabio Tortora1, Alberto Negro1, Ludovica F S Grasso2, Annamaria Colao2, Rosario Pivonello2, Alessandra Splendiani3, Luca Brunese4, Ferdinando Caranci4. 1. Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. 2. Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy. 3. Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. 4. Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy.
Abstract
BACKGROUND: Growth hormone (GH)-secreting pituitary adenomas, responsible for the development of acromegaly, are the second most frequent type of secreting pituitary adenomas and are characterized by very variable T2-weighted signal intensity on pituitary magnetic resonance imaging (MRI). Previous data have demonstrated a correlation between T2-weighted tumor signal intensity and response to therapy with conventional somatostatin analogs (SSA) in patients with acromegaly. The aim of the current retrospective study was to investigate the correlation between the T2-weighted tumor signal on pituitary MRI and both biochemical and radiological response to first-line SSA therapy. METHODS: Twenty-two naive patients with acromegaly were eligible for the study (14 females and 8 males, mean age ± SD: 58.8±15.74). A biochemical evaluation (GH and IGF-I levels) and an MRI assessment (volume and signal intensity analysis of adenoma) were conducted in each patient at diagnosis and after 12 months of SSA therapy. RESULTS: On diagnostic pituitary MRI, 16 (72.7%) adenomas were T2- hypointense and 6 (27.2%) T2-hyperintense. After 12 months of SSA therapy, IGF-I levels decreased by more than 50% from baseline in 62.5% of patients with T2-hypointense and 33.3% of patients with T2- hyperintense tumor signal, respectively (P=0.03). Moreover, GH levels decreased by more than 80% from baseline in 81.3% and 33.3% of patients with T2-hypointense and T2-hyperintense tumor signal (P=0.02). A significant tumor volume reduction (≥20%) was observed in 75% of the T2-hypointense and 33.3% of the T2-hyperintense adenomas (P=0.001). CONCLUSIONS: In naive patients with acromegaly, first-line SSA therapy is associated with a better biochemical response and greater tumor shrinkage in T2-hypointense compared to T2-hyperintense adenomas. Therefore, T2-weighted sequences of pituitary MRI can help to classify GH-secreting pituitary adenomas into a T2-hypointense and T2-hyperintense type and, therefore, to identify patients who can better respond to first-line SSA therapy.
BACKGROUND: Growth hormone (GH)-secreting pituitary adenomas, responsible for the development of acromegaly, are the second most frequent type of secreting pituitary adenomas and are characterized by very variable T2-weighted signal intensity on pituitary magnetic resonance imaging (MRI). Previous data have demonstrated a correlation between T2-weighted tumor signal intensity and response to therapy with conventional somatostatin analogs (SSA) in patients with acromegaly. The aim of the current retrospective study was to investigate the correlation between the T2-weighted tumor signal on pituitary MRI and both biochemical and radiological response to first-line SSA therapy. METHODS: Twenty-two naive patients with acromegaly were eligible for the study (14 females and 8 males, mean age ± SD: 58.8±15.74). A biochemical evaluation (GH and IGF-I levels) and an MRI assessment (volume and signal intensity analysis of adenoma) were conducted in each patient at diagnosis and after 12 months of SSA therapy. RESULTS: On diagnostic pituitary MRI, 16 (72.7%) adenomas were T2- hypointense and 6 (27.2%) T2-hyperintense. After 12 months of SSA therapy, IGF-I levels decreased by more than 50% from baseline in 62.5% of patients with T2-hypointense and 33.3% of patients with T2- hyperintense tumor signal, respectively (P=0.03). Moreover, GH levels decreased by more than 80% from baseline in 81.3% and 33.3% of patients with T2-hypointense and T2-hyperintense tumor signal (P=0.02). A significant tumor volume reduction (≥20%) was observed in 75% of the T2-hypointense and 33.3% of the T2-hyperintense adenomas (P=0.001). CONCLUSIONS: In naive patients with acromegaly, first-line SSA therapy is associated with a better biochemical response and greater tumor shrinkage in T2-hypointense compared to T2-hyperintense adenomas. Therefore, T2-weighted sequences of pituitary MRI can help to classify GH-secreting pituitary adenomas into a T2-hypointense and T2-hyperintense type and, therefore, to identify patients who can better respond to first-line SSA therapy.
Authors: Adrian F Daly; Martine Rixhon; Christelle Adam; Anastasia Dempegioti; Maria A Tichomirowa; Albert Beckers Journal: J Clin Endocrinol Metab Date: 2006-09-12 Impact factor: 5.958
Authors: Sven M Carlsen; Morten Lund-Johansen; Thomas Schreiner; Sylvi Aanderud; Oivind Johannesen; Johan Svartberg; John G Cooper; John K Hald; Stine L Fougner; Jens Bollerslev Journal: J Clin Endocrinol Metab Date: 2008-05-20 Impact factor: 5.958
Authors: Ericka B Trarbach; Giampaolo Trivellin; Isabella P P Grande; Felipe H G Duarte; Alexander A L Jorge; Felipe Barjud Pereira do Nascimento; Heraldo M Garmes; Marcia Nery; Berenice B Mendonca; Constantine A Stratakis; Marcello D Bronstein; Raquel S Jallad Journal: Pituitary Date: 2020-11-06 Impact factor: 4.107
Authors: Alireza Ghajar; Pamela S Jones; Francisco J Guarda; Alex Faje; Nicholas A Tritos; Karen K Miller; Brooke Swearingen; Lisa B Nachtigall Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958